Current and Upcoming Studies

The Northeast Iowa Medical Education Foundation Research Department is working toward solutions for patients living with complex diseases. We do this through clinical trials, which may offer qualified patients an alternate therapy.

Your participation in these studies would assist the pharmaceutical and health care industries in developing new and effective medications for your medical condition. (All medications currently available by prescription underwent clinical study to be FDA approved.) 

To participate in any of the studies listed below, please take a moment to complete a short interest form. Our experienced and professional research colleagues, who have been trained to treat multitudes of medical conditions and illnesses, will follow up to screen you according to the trial’s requirements. They will also review the clinical trial with you, so you understand the treatment, medication and protocols should you join the trial.

CURRENTLY ENROLLING VOLUNTEERS: 
TRAILBLAZER-ALZ 3 Addendum 7, Pre-Clinical Alzheimer’s

• Currently enrolling!
• Protocol No. I5T-MC-AACM
• Sponsor: Eli Lilly

This Phase 3 clinical trial is seeking volunteers aged 55-80 curious about their risk of developing Alzheimer’s dementia. This trial evaluates two different schedules of the medication, donanemab, in preventing the onset of Alzheimer’s symptoms in at-risk individuals. 
 

ENROLLING VOLUNTEERS SOON:

ARTEMIS, Cardiovascular Risk Reduction in Post-Heart Attack Patients

• Coming soon!
• Protocol No. EX6018-4979
• Sponsor: NovoNordisk & the Duke University Clinical Research Insititute 

This Phase 3 trial will determine if the medication, ziltivekimab, can be used reduce the risk of stroke or repeat heart attacks in patients admitted to the hospital because of a heart attack. 
 

ONGOING STUDIES:

TRAILBLAZER-ALZ 2, Alzheimer’s

• Active, no longer enrolling
• Protocol No. I5T-MC-AACI
• Sponsor: Eli Lilly 

This Phase 3 double-blinded trial is evaluating the safety and efficacy of the medication, Kisunla (donanemab), in volunteers with early symptomatic Alzheimer’s disease. 

TRAILBLAZER-ALZ 3, Pre-Clinical Alzheimer’s 

• Active, no longer enrolling
• Protocol No. I5T-MC-AACM
• Sponsor: Eli Lilly

This Phase 3 double-blinded trial is evaluating the safety and efficacy of the medication, Kisunla (donanemab), in volunteers with pre-clinical Alzheimer’s disease.

TRAILRUNNER-ALZ 1, Alzheimer’s

• Active, no longer enrolling
• Protocol No. J1G-MC-LAKC
• Sponsor: Eli Lilly 

This Phase 3 study is collecting safety and efficacy information regarding the drug, remternetug, in participants with early symptomatic Alzheimer's disease.

VICTORION-2 PREVENT, High Cholesterol

• Active, no longer enrolling
• Protocol No. CKJX839B12302
• Sponsor: Novartis 

This Phase 3 double-blinded trial is evaluating if an injection of the FDA-approved medication, inclisiran (Leqvio), every 6 months in addition to a daily statin medication can reduce the risk of major cardiovascular events (death, heart attack, or stroke) in patients with an established history of heart disease.